版本:
中国

BRIEF-Biohaven's Trigriluzole receives fast track designation from U.S. FDA

May 15 Biohaven Pharmaceutical Holding Company Ltd

* Biohaven's trigriluzole receives fast track designation from U.S. FDA

* Currently conducting a phase 2/3 clinical trial in patients with sca, with topline results expected in 2018 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐